Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and tumor characteristics

From: Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response

Characteristic Values (n = 56 patients)
Age  
 Median, range 40 (23–74)
Tumor stage  
 1 5 (9)
 2 40 (71)
 3 7 (13)
 4 4 (7)
Nodal stage  
 Lymph nodes negative 19 (34)
 Lymph nodes positive 37 (66)
Grade  
 II 18 (32)
 III 34 (61)
 Not determined 4 (7)
Chemotherapy  
 6 × dose dense doxorubicin/cyclophosphamide 43 (77)
 3 × dose dense doxorubicin/cyclophosphamide, 3 × docetaxel/capecitabine 5 (9)
 4 × dose dense doxorubicin/cyclophosphamide, 2 × cyclophosphamide/thiotepa/carboplatin 8 (14)
BRCA germline mutation status (Sanger sequencing)  
BRCA1 mutation 10 (18)
BRCA2 mutation 2 (4)
 Wildtype 39 (70)
 Not determined 5 (9)
BRCA1 promoter methylation  
 No BRCA1 methylation 39 (70)
BRCA1 methylation 17 (30)
Response breast and lymph nodes  
 No pathological complete remission 31 (55)
 Pathological complete remission 25 (45)
Relapse  
 No relapse 47 (84)
 Relapse 9 (16)
  1. Values are n (%) unless stated otherwise